

RESOLUTION

THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JOINT STOCK COMPANY (BIDIPHAR)

Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and its amending, supplementing, and guiding documents;

Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, and its amending, supplementing, and guiding documents (“Law on Securities”);

Pursuant to the Company’s Charter of Binh Dinh Pharmaceutical and Medical Equipment JSC;

Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. /BB-DHĐCĐ2026 dated 25/04/2026,

APPROVED

ARTICLE 1. APPROVAL OF THE REPORT ON THE BOARD OF DIRECTORS’ ACTIVITIES IN 2025

The General Meeting of Shareholders approved the Report on Board of Directors' Activities in 2025 with the following key indicators:

No.	Items	Unit	Plan in 2025	Actual in 2025	Actual/Plan (%)	Actual in 2024	% Actual 2025/2024
1	Charter Capital	Billion VND	936	945	101%	936	101%
2	Total Revenue	Billion VND	2.000	1.947	97%	1.817	107%
3	Profit Before Tax	Billion VND	335	344	103%	325	106%

ARTICLE 2. APPROVAL OF THE 2025 DIVIDEND PAYMENT PLAN

The General Meeting of Shareholders approved the cash dividend payment plan for 2025 as follows:

- Dividend rate: 20% of par value, equivalent to VND 2.000 per share.
- Authorization to the Board of Directors: to decide the record date/final registration date and the payment date, but no later than 6 months from April 25, 2026.

- Source of payment: from undistributed after-tax profits according to the audited consolidated financial statements for the fiscal year ended December 31, 2025.

ARTICLE 3. APPROVAL OF THE REPORT OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS FOR THE YEAR 2025

The General Meeting of Shareholders approved the Report of Independent Members of the Board of Directors in for the year 2025.

ARTICLE 4. APPROVAL OF AUDITED FINANCIAL STATEMENT FOR THE YEAR 2025

The General Meeting of Shareholders approved the Financial Statements of the Company for the year 2025 (separate and consolidated), audited by the ERNST & YOUNG Viet Nam Co., Ltd.

ARTICLE 5. APPROVAL OF BUSINESS PLAN FOR THE YEAR OF 2026

The General Meeting of Shareholders approved the 2026 Business Plan with the following key indicators (consolidated):

No.	Items	Unit	2025 Performance	2026 Plan	% Growth
1	Charter capital	Billion VND	945	945	0%
2	Total revenue	Billion VND	1.947	2.090	+7%
3	Pre-tax profit	Billion VND	344	375	+9%
4	Dividend rate (cash or shares)	%	20% of par value in cash	Minimum 20% of par value in cash or shares	-

ARTICLE 6. APPROVAL OF THE SELECTION OF THE AUDIT FIRM FOR THE FINANCIAL YEAR 2026

The General Meeting of Shareholders instructed the Board of Directors to decide on the selection of one of four auditing companies from the list of auditing companies (inclusive of their affiliated branches) approved by the State Securities Commission of Vietnam to audit entities with interests in the securities areas proposed below to perform audit work for Financial Statements of the financial year 2026 of Bidiphar:

1. PwC Co., Ltd (Viet Nam)
2. Deloitte Viet Nam Co., Ltd
3. ERNST & YOUNG Viet Nam Co., Ltd
4. KPMG Co., Ltd

For other audit activities that may arise in the 2026 fiscal year, the General Meeting of Shareholders authorizes the Board of Directors to decide on the selection of an audit firm from the list of audit firms approved by the State Securities Commission.

ARTICLE 7. APPROVAL OF PROFIT DISTRIBUTION, FUND ALLOCATIONS FOR 2025, AND PROFIT DISTRIBUTION PLAN FOR 2026

1. The General Meeting of Shareholders approved the profit distribution and fund allocations for 2025 as follows:

No.	Items	Plan in 2025	Actual in 2025	Amount (VND)
I	Consolidated net profit of the parent company in 2025	100% Net profit after tax (NPAT)	100% Net profit after tax (NPAT)	291.940.164.606
II	Fund distribution			49.629.827.982
1	Development investment fund	10% NPAT	10% NPAT	29.194.016.460
2	Reward and welfare fund	10% NPAT	3% NPAT	8.758.204.938
3	Board of Directors and Internal Audit remuneration	2% NPAT	2% NPAT	5.838.803.292
4	Executive Board bonus	2% NPAT	2% NPAT	5.838.803.292
III	Remaining profit after distribution to the Funds in 2025 (III) = (I) - (II)	-	-	242.310.336.624
IV	Dividend distribution (in cash and/or shares)	Minimum 20% of par value, in cash or in shares	20% of par value in cash, equivalent to 65% of NPAT	188.978.524.000
V	Remaining profit in 2025 (V) = (III) - (IV)	Remaining NPAT	Remaining NPAT	53.331.812.624

The General Meeting of Shareholders authorizes the Board of Directors to determine the appropriate timing and method of dividend payment to shareholders based on the Company's business performance and financial situation. The Board of Directors is also authorized to decide on all related matters necessary to complete the dividend payment or advance distribution to shareholders.

2. The General Meeting of Shareholders approved the 2026 Profit Distribution Plan as follows:

No.	Items	Plan in 2026
I	Consolidated net profit of the parent company in 2026	100% Net profit after tax (NPAT)
II	Fund distribution	
1	Development investment fund	10% NPAT
2	Reward and welfare fund	3% NPAT
3	Board of Directors and Internal Audit remuneration	2% NPAT
4	Executive Board bonus	2% NPAT
III	Dividend distribution (in cash and/or shares)	Minimum 20% of par value, in cash or in shares.
IV	Remaining profit (IV) = (I) - (II) - (III)	Remaining NPAT

ARTICLE 8. APPROVAL OF AMENDMENTS AND SUPPLEMENTS TO THE SHARE ISSUANCE PLAN UNDER THE EMPLOYEE STOCK OPTION PROGRAM (ESOP)

The General Meeting of Shareholders approves the share issuance plan under the ESOP of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar), to be funded from owners' equity, in accordance with the detailed contents set out in Appendix 01 attached to this Resolution.

ARTICLE 9. APPROVAL OF THE PRIVATE PLACEMENT PLAN FOR INVESTORS

The General Meeting of Shareholders approves the private placement plan for investors and authorizes the Company's Board of Directors to implement it in accordance with the detailed provisions set forth in Appendix 02 attached to this Resolution.

ARTICLE 10. APPROVAL OF AMENDMENTS TO THE COMPANY'S BUSINESS LINES

The General Meeting of Shareholders approves the amendments to the Company's business lines in accordance with the detailed contents set out in Appendix 03 attached to this Resolution.

ARTICLE 11. APPROVAL OF AMENDMENTS AND SUPPLEMENTS TO THE COMPANY CHARTER AND INTERNAL REGULATIONS ON CORPORATE GOVERNANCE

The General Meeting of Shareholders approved the amendments and supplements to the Company Charter and the Internal Corporate Governance Regulations. The full text of the Company Charter, Internal Corporate Governance Regulations is attached to this Resolution. The newly approved Company Charter and Internal Corporate Governance Regulations shall take effect from the date of issuance and shall replace the most recently amended versions.

ARTICLE 12. ASSIGN THE BOARD OF DIRECTORS TO ORGANIZE IMPLEMENTATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS' RESOLUTION.

The Board of Directors, along with the Chairperson of the Board of Directors, is entrusted with the responsibility for effectively executing the resolutions outlined in this Resolution by the General Meeting of Shareholders. This includes ensuring compliance with all relevant laws, the Company's Charter of Organization and Operation, internal regulations on corporate governance, operating regulations of the Board of Directors, and complete information disclosure as mandated by law.

The delegation of powers and responsibilities by the General Meeting of Shareholders remains effective until the Board of Directors/Chairperson of the Board of Directors has successfully completed the assigned tasks, or until the General Meeting of Shareholders issues a Resolution for any necessary changes.

ARTICLE 12. THIS RESOLUTION WAS APPROVED BY THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JOINT STOCK COMPANY (BIDIPHAR) ON APRIL 25, 2026, AND TAKES EFFECT FROM THE DATE OF SIGNING.

Recipients:

- *Shareholders of Bidiphar;*
- *BOD, Audit Committee;*
- *Executive Board;*
- *SSC, HOSE, VSDC;*
- *Stored at Company Secretary Office.*

**ON BEHALF OF THE 2026 ANNUAL GENERAL
MEETING OF SHAREHOLDERS
CHAIRMAN**

TẠ NAM BÌNH

APPENDIX 01

Plan to issue shares under the Employee Stock Ownership Plan (ESOP) of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar) from owners' equity (Attached to Resolution No. ___/NQ-DHĐCĐ2026 dated 25/04/2026)

I. ESOP issuance plan from owners' equity

Security Name	:	Shares of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar).
Stock Code	:	DBD.
Type of Security	:	Common shares.
Par Value	:	10.000 VND.
Number of shares issued	:	94.529.347 shares (<i>In words: Ninety-four million five hundred twenty-nine thousand three hundred forty-seven shares</i>)
Tổng giá trị cổ phiếu đã phát hành (theo mệnh giá)	:	945.293.470.000 VND (<i>In words: Nine hundred forty-five billion two hundred ninety-three million four hundred seventy thousand Vietnamese dong.</i>)
Number of outstanding shares	:	94.489.262 shares (<i>In words: Ninety-four million four hundred eighty-nine thousand two hundred sixty-two shares.</i>)
Number of treasury shares	:	40.085 shares (<i>In words: Forty thousand eighty-five shares.</i>)
Number of Shares to be Issued	:	1.500.000 shares (<i>In words: One million five hundred thousand shares</i>), equivalent to 1.59% of the total outstanding shares, to be implemented in two phases: <ol style="list-style-type: none"> 1. Phase 1: Issuance of 750.000 shares, representing 50% of the total number of shares proposed for issuance. 2. Phase 2: Issuance of 750.000 shares, representing 50% of the total number of shares proposed for issuance.
Total Par Value of Shares Issued	:	15.000.000.000 VND (<i>In words: fifteen billion VND</i>), including: <ol style="list-style-type: none"> 1. Phase 1: 7.500.000.000 VND (in words: seven billion five hundred million VND). 2. Phase 2: 7.500.000.000 VND (in words: seven billion five hundred million VND).
Issuance timeline	:	<ol style="list-style-type: none"> 1. Phase 1: In 2027, subject to the following conditions: <ul style="list-style-type: none"> - Completion of GMP-EU certification for the Oncology Drug Manufacturing Plant Project by 31 December 2026; and - Receipt of written approval from the State Securities Commission of Vietnam. 2. Phase 2: In 2029, subject to the following conditions: <ul style="list-style-type: none"> - Completion of GMP-EU certification for the Small-Volume Sterile Injectable Drug Manufacturing Plant Project by 31 December 2028; and - Receipt of written approval from the State Securities Commission of Vietnam.
Issuance conditions	:	The ESOP issuances mentioned above shall only be implemented when all prescribed conditions are satisfied. In the event that these conditions are not met, the ESOP issuance shall not be carried out and will be cancelled, unless otherwise approved by the General Meeting

of Shareholders.

Purpose of the issuance	: - To strengthen employee engagement, encouragement, and motivation, thereby promoting active contributions toward the achievement of the Company's strategic objectives; - To ensure the Company's sustainable growth and long-term development.
Eligible recipients for issuance	: Employees of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar) (collectively referred to as the "Employees").
Source of owners' equity used for the issuance	: 1. Phase 1: To be funded from undistributed profit after tax as at 31 December 2026, based on the Company's audited consolidated financial statements for 2026. 2. Phase 2: To be funded from undistributed profit after tax as at 31 December 2028, based on the Company's audited consolidated financial statements for 2028.
Employee Eligibility Criteria	: 1. Phase 1 Employees falling into at least one (01) of the following two (02) categories: a. Employees who are members of the Executive Management. b. Employees holding managerial positions (including Heads/Deputy Heads of departments or equivalent) and other employees who meet the following criteria: ✓ Directly or indirectly perform tasks related to the GMP-EU Oncology Drug Manufacturing Plant Project; ✓ Play a key role in the successful implementation of the project. 2. Phase 2 Employees falling into at least one (01) of the following two (02) categories: a. Employees who are members of the Executive Management. b. Employees holding managerial positions (including Heads/Deputy Heads of departments or equivalent) and other employees who meet the following criteria: ✓ Directly or indirectly perform tasks related to the GMP-EU Small-Volume Sterile Injectable Drug Manufacturing Plant Project; ✓ Play a key role in the successful implementation of the project.
Transfer restriction conditions	: All shares issued under the Employee Stock Ownership Plan (ESOP) of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) are subject to a transfer restriction for four (4) years from the date of completion of the issuance.
Terms for share repurchase and resale of repurchased shares	: As specifically stipulated in the Regulations on Share Issuance under the Employee Stock Ownership Plan (ESOP) of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company

(Bidiphar).

The General Meeting of Shareholders authorizes the Board of Directors to determine the terms for share repurchase and resale of repurchased shares, ensuring compliance with legal regulations and the Company's actual situation at the time of implementation.

II. Implementation Organization

The General Meeting of Shareholders approve to authorize the Board of Directors to carry out the following tasks:

- a) Decide the specific number of shares to be issued, provided that in all cases such number shall not exceed 1.6% (one point six percent) of the total outstanding shares at the time of issuance;
- b) Decide on an appropriate timing for the implementation of the issuance of shares under the Employee Stock Ownership Plan of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar);
- c) In the event that the prevailing laws at the time of implementation permit the Board of Directors to determine the eligibility criteria for employees participating in the ESOP, the General Meeting of Shareholders authorizes the Board of Directors to amend and supplement the eligibility criteria for ESOP participation in a manner that maximizes benefits for shareholders and employees, while ensuring compliance with actual circumstances and applicable laws;
- d) Decide and approve measures to ensure that the share issuance complies with regulations on foreign ownership limits in cases where the issuance is made to employees who are foreign investors;
- e) Decide on the development and promulgation of the Regulations on the issuance of shares under the Employee Stock Ownership Plan of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar); decide on specific criteria, the list of eligible participants, principles for determining the number of shares allocated to each participant, the number of shares each employee is entitled to under the program, rounding principles for share allocation, as well as provisions on share clawback and disposal of reclaimed shares;
- f) Decide to supplement, amend, finalize, and provide explanations for all matters and contents of the ESOP issuance plan of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar) (including matters not fully presented in this capital increase plan), and to execute relevant documents to carry out the capital increase in accordance with applicable laws when completing procedures for the increase of charter capital;
- g) Decide on amendments to provisions relating to charter capital, shares, and share certificates in the Charter of Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company (Bidiphar) in accordance with the actual charter capital upon completion of all share issuance tranches;
- h) Decide on amendments to the Enterprise Registration Certificate in accordance with the actual charter capital upon completion of all share issuance tranches;

- i) Carry out procedures for amending the registration of additional depository shares and for registering the additional listing of shares with competent State authorities in accordance with applicable laws upon completion of all issuance tranches;
- j) Authorize the Board of Directors to consider and select consulting service providers (if necessary) and proactively implement tasks related to the issuance in compliance with applicable laws; and
- k) Decide on other matters arising in order to complete the implementation of the charter capital increase.

APPENDIX 02
PLAN FOR PRIVATE PLACEMENT OF SHARES TO INVESTORS
(Attached to Resolution No. ___/NQ-DHĐCĐ2026 dated 25/04/2026)

1. Private placement plan

Name of the shares to be offered	: Shares of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar).
Share type	: Common shares
Stock code	: DBD.
Par value	: VND 10.000 per share
Offering currency	: Vietnam Dong (VND)
Total number of outstanding shares	: 94.489.262 shares (<i>In words: Ninety-four million four hundred eighty-nine thousand two hundred sixty-two shares</i>)
Charter capital	: 945.293.470.000 VND (<i>In words: Nine hundred forty-five billion two hundred ninety-three million four hundred seventy thousand Vietnam Dong</i>)
Total number of shares proposed to be offered	: 23.300.000 shares (<i>In words: Twenty-three million three hundred thousand shares</i>)
Total offering value (at par value)	: 233.000.000.000 VND (<i>In words: Two hundred thirty-three billion Vietnam Dong</i>)
Offering method	: Private placement of shares.
Placement method	: Private placement to professional securities investors.
Principle for determining the offering price	: The specific offering price shall be determined by the Board of Directors through direct negotiation with investors, but shall not be lower than 50.000 VND per share. The General Meeting of Shareholders authorizes the Board of Directors to determine the specific offering price at the time of the offering based on negotiation and agreement with investors in the private placement, in accordance with the pricing principles approved by the General Meeting of Shareholders.
Purpose of the offering	: To supplement equity capital, enhance financial capacity for investment in the pharmaceutical manufacturing plant project, and provide additional working capital for the Company's business operations.
Criteria for selecting investors	: Organizations, domestic and/or foreign, that meet the criteria and conditions of professional securities investors as stipulated in the Securities Law. Possess strong financial capacity and commit to accompanying and supporting the Company in its business operations, corporate governance, and financial activities to facilitate the Company's development and ensure the interests of shareholders.
Number of investors	: Up to 05 (five) professional securities investors. The General Meeting of Shareholders authorizes the Board of Directors to decide the list of professional securities investors participating in the private placement, ensuring compliance with

		the investor selection criteria approved by the General Meeting of Shareholders, and to determine the number of shares allocated to each investor.
Transfer restrictions	:	The privately placed shares mentioned above shall be subject to a transfer restriction of 01 year from the completion date of the offering, except for transfers between professional securities investors or transfers made pursuant to a legally effective court judgment or decision, an arbitral award, or inheritance in accordance with applicable laws.
Plan for handling unsubscribed shares	:	Any shares not fully subscribed by the initially identified investors (if any) shall be allocated by the Board of Directors to other professional securities investors at a price not lower than the offering price determined in accordance with the pricing principles approved by the General Meeting of Shareholders. These additionally allocated shares shall also be subject to a transfer restriction of 01 year from the completion date of the offering. If the distribution period prescribed by law expires and the shares remain unsubscribed, such remaining shares shall be cancelled and the offering shall be terminated. The Company shall increase its charter capital based on the actual number of shares successfully issued.
Expected issuance timeline	:	Expected to be implemented in 2026 or 2027, after investors are selected and approval is obtained from the State Securities Commission of Vietnam.
Additional securities registration and listing registration	:	All successfully issued shares will be additionally registered with the Vietnam Securities Depository and Clearing Corporation and additionally listed on the Ho Chi Minh City Stock Exchange in accordance with applicable regulations.
Public tender offer	:	In the event that the ownership ratio of investors participating in the private placement results in their shareholding exceeding the threshold specified in Clause 1, Article 35 of the Securities Law, such investors shall not be required to conduct a public tender offer.
Approval of charter capital adjustment	:	Approval of the adjustment of the Company's charter capital in the Company Charter and amendment of the Enterprise Registration Certificate with the Business Registration Authority after receiving written notification from the State Securities Commission of Vietnam confirming receipt of the report on the results of the offering.

2. Plan for the use of proceeds from the offering

The expected proceeds from the private placement are VND 1,165,000,000,000 (In words: One trillion one hundred sixty-five billion Vietnam Dong) (calculated based on the minimum offering price of VND 50,000 per share in accordance with the pricing principle and assuming the successful issuance of 23,300,000 shares). After deducting expenses related to

the offering, the proceeds will be used to invest in the Company's projects in the following order of priority::

- *1) Small Volume Sterile Injection (SVI) Manufacturing Plant Project, with a total estimated investment of VND 840,000,000,000 (Eight hundred forty billion Vietnam Dong), pursuant to the Resolution of the 2023 Annual General Meeting of Shareholders No. 490/NQ-DHĐCĐ dated April 21, 2023; and*
- *(2) OSD Non-Betalactam Manufacturing Plant Project, with a total estimated investment of VND 870,000,000,000 (Eight hundred seventy billion Vietnam Dong), pursuant to the Resolution of the 2024 Annual General Meeting of Shareholders No. 749/NQ-DHĐCĐ dated April 27, 2024.*

Pending disbursement in accordance with the above plan, the proceeds from the share offering may be placed in short-term deposits at banks. The General Meeting of Shareholders authorizes the Board of Directors to determine the specific timing of disbursement based on project implementation progress and the Company's actual situation, ensuring maximum benefits for shareholders and without affecting the Company's capital sources or its regular business operations, and to report to the nearest General Meeting of Shareholders.

Plan to cover any funding shortfall: The Company will flexibly utilize other internal funding sources, bank borrowings, or other lawful financing sources to cover any funding shortfall required to implement the above-mentioned investment purposes..

3. Implementation arrangements

The General Meeting of Shareholders approve the authorization of the Board of Directors to carry out the following tasks:

- 1) Select an appropriate timing and carry out the necessary procedures to implement the offering plan in accordance with the Company Charter and applicable laws, ensuring the interests of shareholders.
- 2) Decide on the list of specific professional securities investors and the number of shares to be offered to each investor in the private placement; decide on adjustments to the list of professional securities investors depending on the actual negotiation progress and the investors' capabilities at each stage.
- 3) Determine the specific offering price at the time of the offering based on negotiation and agreement with investors in the private placement, in accordance with the pricing principles approved by the General Meeting of Shareholders.
- 4) Approve the plan to ensure that the private placement complies with foreign ownership limits.
- 5) Decide on the detailed plan for the use of proceeds, the timing of disbursement and the purposes of capital utilization when necessary and in line with the Company's actual situation, while ensuring compliance with regulations of competent authorities in accordance with applicable laws; decide on adjustments to the use-of-proceeds plan and the amount of funds raised from the private placement with a change value of less than 50% of the total capital raised, and report such changes (if any) to the nearest General Meeting of Shareholders.

- 6) Based on the actual proceeds received and the Company's practical situation, proactively implement plans to cover any funding shortfall for project investments when necessary.
- 7) Decide on the handling of unsubscribed shares in the offering in accordance with the principles approved by the General Meeting of Shareholders.
- 8) Carry out procedures for the registration of charter capital adjustment after receiving written notification from the State Securities Commission of Vietnam confirming receipt of the report on the results of the offering.
- 9) Amend the Company Charter (due to the change in charter capital) after receiving written notification from the State Securities Commission of Vietnam confirming receipt of the report on the results of the offering.
- 10) Carry out procedures for amending the Enterprise Registration Certificate in accordance with applicable laws.
- 11) Register additional securities depository and additional listing for the successfully issued shares in accordance with applicable regulations.
- 12) In addition to the authorizations mentioned above, during the implementation of the offering plan, the General Meeting of Shareholders authorizes the Board of Directors to supplement, amend, and finalize the offering plan as required by competent state authorities and/or in accordance with the Company's actual situation, ensuring that the offering is conducted legally, in compliance with regulations, and in the best interests of the Company and its shareholders.

APPENDIX 03
PLAN FOR PRIVATE PLACEMENT OF SHARES TO INVESTORS
(Attached to Resolution No. ___/NQ-DHĐCĐ2026 dated 25/04/2026)

The Company's business lines after being amended are as follows:

No.	Name of business lines	Business line codes
1.	<p>Manufacture of pharmaceuticals, medicinal chemical and botanical products</p> <p>Details: Manufacture of pharmaceuticals, pharmaceutical materials, medicinal chemical and botanical products.</p>	2100 (Main business)
2.	<p>Wholesale of other household products</p> <p>Details: Trading in pharmaceuticals produced by the Company; Exporting botanical products and pharmaceuticals according to regulations of the Ministry of Health; Importing finished pharmaceutical products and cosmetics; Trading, importing and exporting cosmetic products.</p>	4649
3.	<p>Retail sale of pharmaceutical and medical goods, cosmetic and toilet articles (4772)</p> <p>Details: Retail sale of pharmaceuticals and botanical products produced by the Company; retail sale of medical supplies, medical masks, medical equipment and instruments in the medical and pharmaceutical sectors; cosmetics, functional foods, health protection foods; insecticides and disinfectants used in the medical and household sectors, except for groups of goods in the National Reserve list according to Decree No. 56/2021/ND-CP dated May 31, 2021 of the Government.</p>	4772
4.	<p>Manufacture of dairy products</p>	1050
5.	<p>Manufacture of other food products n.e.c</p> <p>Details: Production of functional foods, health protection foods, supplementary foods, fortified foods and micronutrients; Production of iodized salt; Production of foods from natural herbs, drinks from medicinal herbs; Production of herbal teas; Production, exploitation and processing of honey.</p>	1079
6.	<p>Wholesale of food</p> <p>Details: Buying and selling dairy products, functional foods, health protection foods, food supplements, fortified foods and micronutrients (except rice, cane sugar, beet sugar); Wholesale of herbal tea and other types of tea; Wholesale of honey and bee products. Wholesale of other foods.</p>	4632
7.	<p>Wholesale of other machinery and equipment</p> <p>Details: Wholesale, import and export of medical supplies, equipment, medical instruments in the medical, pharmaceutical and other scientific and technical sectors, equipment and instruments used for laboratories (physics-chemistry-</p>	4659

No.	Name of business lines	Business line codes
	biology) except for groups of goods in the National Reserve list according to Decree No. 56/2021/ND-CP dated May 31, 2021 of the Government.	
8.	<p>Other specialized wholesale n.e.c</p> <p>Details: Trading, importing and exporting veterinary pharmaceutical ingredients; Importing and exporting materials for human medicine when permitted by the Ministry of Health and competent authorities (Importing raw materials for medicine does not include performing activities directly related to the distribution of raw materials for medicine in Vietnam, except for raw materials for medicine produced by the Company in Vietnam); Trading, importing and exporting testing chemicals, vaccines, biological products for human use, packaging types produced in the fields of medicine, pharmacy, food, cosmetics; Wholesale, importing and exporting industrial chemicals, cleaning chemicals, insecticides, disinfectants; Functional foods.</p> <p>Except for chemicals that are not allowed to be traded, wholesaled, or retailed according to Appendix 2 of the Investment Law 2014 and chemicals prohibited from distribution and export according to Circular 34/2013/TT-BCT).</p> <p>The Company does not provide third-party pharmaceutical distribution services in the Vietnamese market.</p>	4779
9.	<p>Manufacture of non-alcoholic beverages, and mineral waters</p> <p>Details: Production of mineral water and soft drinks.</p>	1105
10.	<p>Manufacture of corrugated paper and paperboard and of containers of paper and paperboard</p> <p>Details: Production of raw paper and carton packaging.</p>	1702
11.	<p>Manufacture of glass and glass products</p> <p>Details: Production of glass bottles and tubes for pharmaceutical and consumer industries.</p>	2310
12.	<p>Freight transport by road</p> <p>Details: Internal transportation by road to serve the company's production activities.</p>	4933
13.	<p>Trading of own or rented property and land use rights</p> <p>Details: Invest in construction of housing or buildings accompanied with LURs for sale, lease or lease purchase through real estate projects which must ensure form, purpose and term of land use as prescribed by the Land Law; Invest in construction of infrastructure facilities within real estate projects for transfer, lease or sublease of rights to use land that already has infrastructure which must ensure form, purpose and term of land use as prescribed by the Land Law; Lease housing, buildings or their floor areas for sublease; Receive transfer of entire or</p>	6810

No.	Name of business lines	Business line codes
	partial real estate project for continuing construction and trading.	
14.	Repair and maintenance of machinery and equipment Details: Repair, maintenance, and servicing of equipment, machinery, and tools in the medical and pharmaceutical manufacturing fields.	3312
15.	Other professional, scientific and technical activities n.e.c. Details: Research, development, and transfer of new products in the pharmaceutical field.	7499
16.	Warehousing and storage Details: Warehousing and warehouse services (excluding warehouse and yard rental).	5210
17.	Repair and maintenance of electronic and optical equipment Details: Repair activities of machinery, medical equipment and diagnostic equipment with display screens, measuring and testing equipment, laboratory equipment, radar equipment and/or underwater object locating equipment using ultrasound or ultrasonic.	3313
18.	Growing of perennial spices, pharmaceutical and aromatic crops	0128
19.	Electrical installation	4321
20.	Manufacture of medical and dental, and orthopedic and rehabilitation instruments and supplies	3250
21.	Plumbing, heat and air-conditioning system installation	4322
22.	Other manufacturing n.e.c. Details: Electrical and refrigeration processing	3290
23.	Growing of rubber trees	0125
24.	Manufacture of other chemical products n.e.c Details: Production of industrial chemicals, cleaning chemicals, insecticides and disinfectants for household and medical use; production of natural essential oils.	2029
25.	Manufacture of cosmetics, perfumes, soap and detergents, cleaning and polishing preparations and toilet preparations	2023
26.	Mixed crop-livestock farming Details: Cultivation and animal husbandry (not animal husbandry at headquarters, not including animal husbandry services and seed source development)	0150
27.	Distilling, rectifying and blending of spirits	1101

No.	Name of business lines	Business line codes
28.	Wholesale of beverages Details: Wholesale, import and export of purified water, natural mineral water and medicinal drinks, non-alcoholic beverages	4633
29.	Manufacture of wines	1102
30.	Raising of other animals Details: Investing in beekeeping for honey	0149
31.	Retail sale of food products Details: Retail of honey and bee products	4722
32.	Wholesale of agricultural raw materials (except wood, bamboo) and live animals Details: Except for goods that foreign-invested enterprises are not allowed to exercise import, export and distribution rights according to Circular No. 34/2013/TT-BCT dated December 24, 2013 of the Ministry of Industry and Trade.	4620
33.	Propagation and care of agricultural cultivars	0132
34.	Growing of vegetables, leguminous crops and flowers	0118
35.	Growing of fruits	0121
36.	Growing of other annual crops	0119
37.	Other retail sale of new goods in specialized stores (except automobiles, motorcycles, mopeds and accessories therefor) Details: Retail of agricultural and forestry products; Retail of flowers and ornamental plants (except for goods that foreign-invested enterprises are not allowed to exercise distribution rights according to Appendix 3 issued with Circular No. 34/2013/TT-BCT dated December 24, 2013 of the Ministry of Industry and Trade).	4773
38.	Retail sale of food Details: Retail of livestock and poultry meat	4722
39.	Technical testing and analysis Details: Testing services for raw materials, packaging, finished pharmaceutical products, medicinal herbs, functional foods, cosmetics	7120
40.	Other human health activities n.e.c Details: Services for preserving medicines, functional foods, and cosmetics; Consulting and management services to ensure quality in the production of	8699

No.	Name of business lines	Business line codes
	medicines, functional foods, and cosmetics.	
41.	Manufacture of plastics products Details: Production of plastic packaging	2220
42.	Activities must ensure conditions and Business License according to regulations.	Business do not match the Vietnam Industry Code